Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02303392
Title Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jennifer Woyach

chronic lymphocytic leukemia

diffuse large B-cell lymphoma

mantle cell lymphoma


Ibrutinib + Selinexor

Age Groups: adult
Covered Countries USA

No variant requirements are available.